NEUROGENE INC (NGNE) — insider trading
Health Care · NASDAQ
NEUROGENE INC (NGNE) has 16 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 16 (latest 2026-09-22).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | McMinn Rachel | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 756 | — | $0 | Form 4 |
| 2026-09-22 | McMinn Rachel | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 756 | $25.32 | $19.1K | Form 4 |
| 2026-07-07 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 4,200 | $36.13 | $151.8K | Form 4 |
| 2026-07-06 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 600 | $36.02 | $21.6K | Form 4 |
| 2026-07-02 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 1,530 | $35.23 | $53.9K | Form 4 |
| 2026-07-02 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 2,531 | $34.58 | $87.5K | Form 4 |
| 2026-07-01 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 739 | $34.06 | $25.2K | Form 4 |
| 2026-05-06 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 4,800 | $32.44 | $155.7K | Form 4 |
| 2026-05-06 | Cvijic Christine Mikail | Director, Officer (President and CFO) | Open-market sale | 4,800 | $30.07 | $144.4K | Form 4 |
| 2026-05-05 | Shafer Christina | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-03-26 | Jordan Julie | Officer (Chief Medical Officer) | Open-market sale | 828 | $21.89 | $18.1K | Form 4 |
| 2026-03-26 | McMinn Rachel | Director, Officer (Chief Executive Officer) | Open-market sale | 3,352 | $22.07 | $74.0K | Form 4 |
| 2026-03-26 | Cvijic Christine Mikail | Officer (President and CFO) | Open-market sale | 2,558 | $21.62 | $55.3K | Form 4 |
| 2025-06-12 | Woods Keith | Director | Grant / award / vesting (derivative) | 12,050 | — | $0 | Form 4/A |
| 2024-06-14 | Woods Keith | Director | Grant / award / vesting (derivative) | 7,700 | — | $0 | Form 4/A |
| 2024-01-16 | Woods Keith | Director | Grant / award / vesting (derivative) | 15,400 | — | $0 | Form 4/A |
Ask the chat about NGNE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: NEUROGENE INC (NGNE).
Last updated 2026-09-22 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.